

# Roland Seiler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4085369/publications.pdf>

Version: 2024-02-01

87  
papers

3,640  
citations

218381

26  
h-index

143772

57  
g-index

94  
all docs

94  
docs citations

94  
times ranked

4568  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2020, 77, 420-433.   | 0.9 | 741       |
| 2  | Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. <i>European Urology</i> , 2017, 72, 544-554.  | 0.9 | 638       |
| 3  | Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. <i>JAMA Oncology</i> , 2017, 3, 1663.  | 3.4 | 219       |
| 4  | Her2 Amplification is Significantly More Frequent in Lymph Node Metastases From Urothelial Bladder Cancer Than in the Primary Tumours. <i>European Urology</i> , 2011, 60, 350-357.  | 0.9 | 138       |
| 5  | Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer. <i>European Urology</i> , 2019, 76, 59-68.   | 0.9 | 112       |
| 6  | Evasion of immunosurveillance by genomic alterations of PPAR $\beta$ /RXR $\alpha$ in bladder cancer. <i>Nature Communications</i> , 2017, 8, 103.   | 5.8 | 107       |
| 7  | Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy. <i>Scientific Reports</i> , 2017, 7, 42713.  | 1.6 | 85        |
| 8  | Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5082-5093.  | 3.2 | 82        |
| 9  | Removal of Limited Nodal Disease in Patients Undergoing Radical Prostatectomy: Long-Term Results Confirm a Chance for Cure. <i>Journal of Urology</i> , 2014, 191, 1280-1285.  | 0.2 | 75        |
| 10 | CCND1/CyclinD1 status in metastasizing bladder cancer: a prognosticator and predictor of chemotherapeutic response. <i>Modern Pathology</i> , 2014, 27, 87-95.   | 2.9 | 74        |
| 11 | Molecular Characterization of Neuroendocrine-like Bladder Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3908-3920.   | 3.2 | 71        |
| 12 | Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer. <i>Journal of Urology</i> , 2015, 194, 1120-1131.  | 0.2 | 64        |
| 13 | Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2746-2755.  | 1.9 | 53        |
| 14 | Evolution of Urothelial Bladder Cancer in the Context of Molecular Classifications. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5670.   | 1.8 | 49        |
| 15 | Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non-muscle-invasive Bladder Cancer: Results of a European Survey. <i>European Urology Focus</i> , 2019, 5, 681-688. | 1.6 | 48        |
| 16 | Does Stepwise Voltage Ramping Protect the Kidney from Injury During Extracorporeal Shockwave Lithotripsy? Results of a Prospective Randomized Trial. <i>European Urology</i> , 2016, 69, 267-273.                          | 0.9 | 43        |
| 17 | Unravelling disparate roles of NOTCH in bladder cancer. <i>Nature Reviews Urology</i> , 2018, 15, 345-357.   | 1.9 | 42        |
| 18 | Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer. <i>Bladder Cancer</i> , 2018, 4, 19-29.   | 0.2 | 41        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer. <i>European Urology</i> , 2017, 72, 142-150.  | 0.9 | 38        |
| 20 | Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis. <i>Genome Medicine</i> , 2019, 11, 60.   | 3.6 | 36        |
| 21 | Tumor Regression Grade of Urothelial Bladder Cancer After Neoadjuvant Chemotherapy. <i>American Journal of Surgical Pathology</i> , 2014, 38, 325-332.   | 2.1 | 34        |
| 22 | Prediction of Lymph Node Metastasis in Patients with Bladder Cancer Using Whole Transcriptome Gene Expression Signatures. <i>Journal of Urology</i> , 2016, 196, 1036-1041.  | 0.2 | 33        |
| 23 | Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 826-836.              | 0.8 | 33        |
| 24 | Androgen receptors are differentially expressed in Gleason patterns of prostate cancer and downregulated in matched lymph node metastases. <i>Prostate</i> , 2011, 71, 453-460.                                      | 1.2 | 32        |
| 25 | Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 413-422.                                 | 0.8 | 32        |
| 26 | Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients. <i>Oncotarget</i> , 2017, 8, 50804-50813.   | 0.8 | 29        |
| 27 | Re: Aurélien Kamoun, Aurélien de Reyni s, Yves Allory, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. <i>Eur Urol</i> 2020;77:420 33. <i>European Urology</i> , 2020, 77, e105-e106. | 0.9 | 29        |
| 28 | Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences. <i>European Urology Oncology</i> , 2020, 3, 420-423.   | 2.6 | 29        |
| 29 | FGFR3 Expression in Primary Invasive Bladder Cancers and Matched Lymph Node Metastases. <i>Journal of Urology</i> , 2015, 193, 325-330.  | 0.2 | 26        |
| 30 | Microhematuria assessment an IBCN consensus Based upon a critical review of current guidelines. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 437-451.                                  | 0.8 | 25        |
| 31 | Multicenter Validation of Histopathologic Tumor Regression Grade After Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1600-1610.           | 2.1 | 24        |
| 32 | Pelvic lymph nodes: distribution and nodal tumour burden of urothelial bladder cancer. <i>Journal of Clinical Pathology</i> , 2010, 63, 504-507.   | 1.0 | 21        |
| 33 | Optimization of Extracorporeal Shock Wave Lithotripsy Delivery Rates Achieves Excellent Outcomes for Ureteral Stones: Results of a Prospective Randomized Trial. <i>Journal of Urology</i> , 2015, 194, 418-423.     | 0.2 | 21        |
| 34 | Update of the ICUD SIU International Consultation on Bladder Cancer 2018: urinary diversion. <i>World Journal of Urology</i> , 2019, 37, 85-93.  | 1.2 | 21        |
| 35 | Molecular footprints of muscle-invasive bladder cancer in smoking and nonsmoking patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 818-825.                                       | 0.8 | 21        |
| 36 | ?- and ?-adrenergic receptor mechanisms in spontaneous contractile activity of rat ileal longitudinal smooth muscle. <i>Journal of Gastrointestinal Surgery</i> , 2005, 9, 227-235.                                  | 0.9 | 20        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Extracapsular extension but not the tumour burden of lymph node metastases is an independent adverse risk factor in lymph node-positive bladder cancer. <i>Histopathology</i> , 2011, 58, 571-578.  | 1.6 | 20        |
| 38 | Forty years of cisplatin-based chemotherapy in muscle-invasive bladder cancer: are we understanding how, who and when?. <i>World Journal of Urology</i> , 2019, 37, 1759-1765.  | 1.2 | 18        |
| 39 | Genomic Subtyping in Bladder Cancer. <i>Current Urology Reports</i> , 2020, 21, 9.  | 1.0 | 18        |
| 40 | MMP-2 and MMP-9 in lymph-node-positive bladder cancer. <i>Journal of Clinical Pathology</i> , 2011, 64, 1078-1082.  | 1.0 | 17        |
| 41 | Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancers. <i>Prostate</i> , 2014, 74, 1647-1654.   | 1.2 | 17        |
| 42 | Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab. <i>European Urology</i> , 2021, 80, 149-159.   | 0.9 | 17        |
| 43 | Predictive models of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer using nuclear morphology and tissue architecture. <i>Cell Reports Medicine</i> , 2021, 2, 100382.   | 3.3 | 17        |
| 44 | Bladder cancer cells secrete while normal bladder cells express but do not secrete AGR2. <i>Oncotarget</i> , 2016, 7, 15747-15756.  | 0.8 | 17        |
| 45 | Assessing the quality of studies on the diagnostic accuracy of tumor markers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1051-1060.   | 0.8 | 16        |
| 46 | Bcl-2 predicts response to neoadjuvant chemotherapy and is overexpressed in lymph node metastases of urothelial cancer of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 166.e1-166.e8.                    | 0.8 | 16        |
| 47 | Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 262-268.    | 0.8 | 15        |
| 48 | Role of Selective $\alpha_1$ and $\alpha_2$ Adrenergic Receptor Mechanisms in Rat Jejunal Longitudinal Muscle Contractility. <i>Journal of Gastrointestinal Surgery</i> , 2008, 12, 1087-1093.  | 0.9 | 14        |
| 49 | Post-translational modifications in bladder cancer: Expanding the tumor target repertoire. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 858-866.  | 0.8 | 14        |
| 50 | Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 573.e19-573.e29.                                     | 0.8 | 13        |
| 51 | Recent progress with next-generation biomarkers in muscle-invasive bladder cancer. <i>International Journal of Urology</i> , 2017, 24, 7-15.  | 0.5 | 12        |
| 52 | Achieving teamwork in naturalistic sport settings: An exploratory qualitative study of informational resources supporting football players' activity when coordinating with others. <i>Psychology of Sport and Exercise</i> , 2018, 38, 154-166.    | 1.1 | 12        |
| 53 | Neuroendocrine Differentiation in Metastatic Conventional Prostate Cancer Is Significantly Increased in Lymph Node Metastases Compared to the Primary Tumors. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1640.                  | 1.8 | 11        |
| 54 | Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 342.e7-342.e14. | 0.8 | 11        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Characteristics of upper urinary tract urothelial carcinoma in the context of bladder cancer: a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 4036-4050.   | 0.6 | 11        |
| 56 | High CD10 expression predicts favorable outcome in surgically treated lymph node–positive bladder cancer patients. <i>Human Pathology</i> , 2012, 43, 269-275.  | 1.1 | 10        |
| 57 | A low or high BMI is a risk factor for renal hematoma after extracorporeal shock wave lithotripsy for kidney stones. <i>Urolithiasis</i> , 2017, 45, 317-321.   | 1.2 | 10        |
| 58 | Role of $\beta$ 1-, $\beta$ 2-, and $\beta$ 3-adrenoceptors in contractile hypersensitivity in a model of small bowel transplantation. <i>Surgery</i> , 2008, 143, 94-102.  | 1.0 | 9         |
| 59 | Team Cognition in Sport: How Current Insights Into How Teamwork Is Achieved in Naturalistic Settings Can Lead to Simulation Studies. <i>Frontiers in Psychology</i> , 2019, 10, 2082.   | 1.1 | 9         |
| 60 | A Consensus Molecular Classification of Muscle-Invasive Bladder Cancer. <i>SSRN Electronic Journal</i> , 0, ,.  | 0.4 | 9         |
| 61 | Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 469-476.  | 0.8 | 8         |
| 62 | Molecular subtypes and response to immunotherapy in bladder cancer patients. <i>Translational Andrology and Urology</i> , 2019, 8, S293-S295.   | 0.6 | 8         |
| 63 | Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2210-2220.   | 1.9 | 8         |
| 64 | Is The Cancer Genome Atlas (TCGA) bladder cancer cohort representative of invasive bladder cancer?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 458.e1-458.e7.   | 0.8 | 7         |
| 65 | New horizons in bladder cancer research. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 867-885.  | 0.8 | 7         |
| 66 | The association of cigarette smoking and pathological response to neoadjuvant platinum-based chemotherapy in patients undergoing treatment for urinary bladder cancer - A prospective European multicenter observational study of the EAU Young Academic Urologists (YAU) urothelial carcinoma working group. <i>Surgical Oncology</i> , 2020, 34, 312-317. | 0.8 | 7         |
| 67 | Impact of tumor size on the oncological outcome of high-grade nonmuscle invasive bladder cancer – examining the utility of classifying Ta bladder cancer based on size. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 851.e19-851.e25.   | 0.8 | 6         |
| 68 | A longitudinal study evaluating interim assessment of neoadjuvant chemotherapy for bladder cancer. <i>BJU International</i> , 2022, 130, 306-313.   | 1.3 | 6         |
| 69 | A showcase study on personalized in silico drug response prediction based on the genetic landscape of muscle invasive bladder cancer. <i>Scientific Reports</i> , 2021, 11, 5849.   | 1.6 | 4         |
| 70 | Seminal Vesical Sparing Cystectomy for Bladder Cancer is Feasible with Good Functional Results without Impairing Oncological Outcomes: A Longitudinal Long-Term Propensity-Matched Single Center Study. <i>Journal of Urology</i> , 2021, 205, 1629-1640.   | 0.2 | 4         |
| 71 | Association of p53-ness with chemo-resistance in urothelial cancers treated with neoadjuvant gemcitabine plus cisplatin.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4512-4512.  | 0.8 | 4         |
| 72 | Predicting response to neoadjuvant chemotherapy in bladder cancer: controversies remain with genomic DNA sequencing. <i>Translational Andrology and Urology</i> , 2016, 5, 271-273.   | 0.6 | 3         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Different stages in drug development for muscle-invasive bladder cancer. <i>Translational Andrology and Urology</i> , 2017, 6, 1060-1066.  | 0.6 | 3         |
| 74 | Conditional analyses of recurrence and progression in patients with TaG1 non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 238.e19-238.e27.   | 0.8 | 3         |
| 75 | Robot-assisted versus open cystectomy. <i>Lancet, The</i> , 2018, 391, 2479-2480.  | 6.3 | 3         |
| 76 | Molecular landscape of carcinoma invading bladder muscle: does patient age matter?. <i>BJU International</i> , 2019, 124, 719-721.   | 1.3 | 3         |
| 77 | Evaluation of carbonic anhydrase IX as a potential therapeutic target in urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 498.e1-498.e11.  | 0.8 | 3         |
| 78 | Pelvic lymph node dissection in the context of radical cystectomy: a thorough insight into the connection between patient, surgeon, pathologist and treating institution. <i>Research and Reports in Urology</i> , 2013, 5, 121.                             | 0.6 | 2         |
| 79 | Uroplakin II as a single marker for luminal versus basal molecular subtypes in muscle invasive urothelial carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 481, 397-403.                       | 1.4 | 2         |
| 80 | Prognostic Role of RNA Expression Molecular Biomarkers in Prostate and Bladder Cancers. <i>European Urology Focus</i> , 2022, 8, 663-666.  | 1.6 | 2         |
| 81 | Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. <i>Eur Urol</i> 2020;77:434-5. <i>European Urology</i> , 2020, 77, 436-438. | 0.9 | 1         |
| 82 | Re: Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. <i>European Urology</i> , 2016, 70, 1076.  | 0.9 | 0         |
| 83 | Editorial: Bladder cancer within the focus of basic and clinical research. Sixth IBCN Seminars Series. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 815-817.   | 0.8 | 0         |
| 84 | Editorial: Basic research in bladder cancer – refining the tools. 3rd IBCN seminars series1. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 855-857.   | 0.8 | 0         |
| 85 | Re: A Clonal Expression Biomarker Associates with Lung Cancer Mortality. <i>European Urology</i> , 2020, 78, 925-926.  | 0.9 | 0         |
| 86 | Adjuvant Treatment of Residual Disease Following Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2020, 6, 525-535.   | 0.2 | 0         |
| 87 | Receptor Activator of NF Kappa B (RANK) Expression Indicates Favorable Prognosis in Patients with Muscle-invasive Bladder Cancer. <i>European Urology Focus</i> , 2022, 8, 718-727.  | 1.6 | 0         |